Smart Pills Market Is Driven By the Growing Demand for Non-invasive and Efficient Drug Delivery Methods

The global smart pills market was valued at USD 4.2 billion in 2022 and it is anticipated to grow further till USD 14.3 billion by 2032, at a CAGR of 13.1% during the forecast period.

Small digital devices known as "smart pills" have a capsule-like shape and are supposed to conduct very complex tasks like sensing, imaging, and medicine administration. When swallowed, these capsules-which may contain a biosensor, an image sensor, a pH sensor, or a chemical sensor-travel along the gastrointestinal track to collect images that would be otherwise challenging to obtain. Additionally, smart pills come with a tiny wearable sensor patch that is linked to a provider portal and an app on a mobile device. These non-invasive tools have transformed how cancer and gastrointestinal problems are diagnosed and can take the place of more traditional diagnostic methods like endoscopy.

Download Sample PDF Of This Report:
https://www.globalinsightservices.com/request-sample/GIS10448/?utm_id=1018

Market Trends and Drivers
One significant driver for the smart pills market is the growing demand for non-invasive and efficient drug delivery methods. Traditional oral drug administration often faces challenges, such as low patient compliance and inadequate absorption rates, which can affect treatment efficacy. Smart pills, equipped with innovative technologies like sensors and microprocessors, enable remote monitoring of medication intake, ensuring patients adhere to their prescribed regimens. Moreover, these pills can target specific areas within the body, releasing drugs at optimal locations for better absorption, thereby enhancing treatment outcomes. As healthcare providers and patients increasingly seek convenient and personalized healthcare solutions, the demand for smart pills is expected to rise, driving the growth of the smart pills market in the coming years.

Major Players in the Global Smart Pills Market
The key players studied in the report are Olympus Corporation, Proteus Digital Health Inc., CapsoVision Inc., MEDTRONIC, FUJIFILM Holdings Corporation, RF Co. Ltd., Check-Cap, BDD Limited, JINSHAN Science & Technology, and MEDISAFE among others.

Request Customization:
https://www.globalinsightservices.com/request-customization/GIS10448/?utm_id=1018

Recent Developments
In January 2021, etectRx, Inc., entered into a partnership agreement with Pear Therapeutics, Inc., for the development of two product candidate in the CNS space integrating adherence sensors and PDTs. The partnership is the first of its kind in exploring the usage of digital pill solutions with PDTs.
In January 2019, Proteus Digital Health launched its first digital cancer chemotherapy pill in the market with an aim to help oncologists track treatment effectiveness and adherence in the cancer patient.
In October 2018, Proteus Digital Health expanded its partnership with Otsuka Pharmaceutical in order to continue the development and commercialization of its ingestible sensor pill platform.
In September 2017, Capso Vision Inc., announced the U.S. launch of Capso Cloud, a managing system that allowed physicians to extract data from the Capso Cam Plus smart pill eliminating the need to process capsule post-ingestion.

Procure Complete Report (PDF with Insights, Charts, Tables, and Figures)
https://www.globalinsightservices.com/checkout/single_user/GIS10448/?utm_id=1018

Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.